Silent Heart Attack Market Overview
Silent Heart Attack Market Size was valued at USD 4.53 Billion in 2023. The Global Silent Heart Attack industry is projected to grow from USD 5.16 Billion in 2024 to USD 12.23 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.14% during the forecast period (2024 - 2032).
In August 2023, the Indian Council of Medical Research (ICMR) has just begun two major studies to investigate the mystery behind the unusually high number of young people dying suddenly after the COVID-19 pandemic. Dr Rajiv Bahl, Director-General of ICMR, told News18 about these audacious projects on the sidelines of the WHO Global Traditional Medicine Summit that was held in Gujarat on August 17 and 18.
PocDoc recently announced in June 2024 that its home test kit for cardiovascular disease (CVD) will include a new feature allowing patients to view test results on their NHS patient records. The PocDoc at-home kit establishes point-of-care diagnostic testing for CVD with a complete cholesterol panel, and data such as heart age, 10-year risk of heart attack or stroke, and BMI are found within the PocDoc app. Patients also get access to further treatment options if required.
In April 2024, Huntington Medical Research Institutes and California Institute of Technology (Caltech), located in Pasadena, witnessed a groundbreaking cardiovascular medicine development when an outstanding, innovative young researcher made significant progress toward developing a noninvasive method for diagnosing heart attacks and heart failure. At present, cardiovascular researchers at the Institutes have made headway in artificial intelligence applications for detecting silent and super-silent heart attacks.
The Indian Bollywood actress, Sushmita Sen, suffered a heart attack on Thursday but she is now doing fine. This information was shared by ‘Sush’ through social media after work last Thursday. To the surprise of many, fitness enthusiast Sushmita Sen had undergone angioplasty after experiencing a sudden cardiac arrest. It is used to reinstate blood flow via narrowed or blocked vessels as performed by medical professionals. In the operation they put in an inflatable balloon at the end of a catheter that goes into this artery. By doing so, it lets more of that fluid flow much easier and prevents clogs from causing heart attacks or strokes later in life. The procedure can be done with or without using a stent which is like a small metallic mesh tube placed inside your arteries to keep them open for you.
Silent heart attack usually does not have any symptoms. The patient may experience chest pain, shortness of breath and cold sweats. It is mostly misunderstood as indigestion, nausea, and other common diseases. The silent heart attack is usually caused due to various factors such as smoking or chewing tobacco, high cholesterol, high blood pressure, diabetes, and obesity. Risk of silent heart attack increases with an increase among the diabetic population and people addicted to smoking. Various imaging tests such as Cardiac Computerized Tomography, Magnetic Resonance Imaging (MRI), electrocardiogram, echocardiogram, blood tests, and others.
According to the Center for Disease Control and Prevention (CDC), as of 2012, nearly half of all adults 117 million population in the U.S. had one or more chronic health conditions. One in four adults were diagnosed with two or more chronic health diseases. Cardiovascular diseases, and diabetes are increasing the economic burden of various developing and developed nations across the globe.
The Silent Heart Attack Market is driven by rising prevalence of chronic diseases such as cardiovascular diseases, diabetes, and others. Furthermore, changing lifestyle, and increasing demand for diagnosis devices for cardiovascular diseases. However, limited number of trained personnel has restrained the growth of market. However, high cost of diagnosis and treatment of cardiovascular diseases also restrains the growth of the market.
Silent Heart Attack Market Segmentation
Silent Heart Attack Market is segmented on the basis of Diagnosis, Indication, Devices, and End User.
On the basis of diagnosis, market is segmented into cardiac computerized tomography, magnetic resonance imaging, electrocardiogram, echocardiogram, blood tests, and others.
On the basis of indication, the market is segmented into medications, coronary angioplasty and stenting, coronary artery bypass surgery, and others.
On the basis of end-user, the market is segmented into hospitals, clinics, diagnostic centers, and others.
Regional Analysis of the Silent Heart Attack Market
America accounts for the largest market for the silent heart attack. The increasing prevalence of cardiovascular diseases and diabetes is the major driving factor for the growth of the market. According to Center of Diseases Control and Prevention (CDC), 9.3% of the total America population is suffering from diabetes. Increasing diabetic and obese population, rising demand for the better treatment for the diseases and well developed infrastructure has provided fuel for the growth of the market. North America accounts for the major share in the American silent heart attack market.
Europe accounts for the second largest market due to a well-developed healthcare sector, continuously increasing patient population and high healthcare expenditure. Additionally, increasing prevalence of diabetes in the European Union (EU) also fuels the market growth. Germany, U.K and France hold the first, second and third position in the Silent Heart Attack Market.
Asia Pacific is expecting the fastest growth for this market. Increasing prevalence of cardiovascular diseases and rapid developments in the healthcare infrastructure are the major driving factors for the growth of the market. India and China are the two major regions with the highest contribution to the market growth owing to the highest diabetic population, and increasing presence of heart attack among these patients. Additionally, rising geriatric population further drive the growth of the market.
In the Middle East & Africa, the market is expected to show steady growth due to the evolving healthcare system, and increasing demand for diagnostic and treatment services. The Middle East is the major contributor for the market which is driven by the presence of well developed economies like Kuwait and Qatar. Whereas, Africa exhibits slow growth due to limited development in the field of medical science and presence of poor economic conditions in various developing regions of Africa.
Key Players in the Silent Heart Attack Market
Some of the key players in Silent Heart Attack Market are:
- Siemens (U.S.)
- Schiller AG
- Midmark Corporation
- Koninklijke Philips N.V. (Japan)
- Bionet (Korea)
- Welch Allyn (U.S.)
- Toshiba Medical Systems Corporation (Japan)
- AstraZeneca plc (U.K)
- Pfizer (U.S.)
- Sanofi (France)
- Merck & Co. (U.S.)
- Daiichi Sankyo Company Limited
- Novartis AG (Germany)
- Bayer (Germany)
- Takeda Pharmaceutical Company Limited (Japan)
- Boehringer Ingelheim GmbH (Germany)
- Astellas Pharma Inc. (Japan)
- Johnson & Johnson (U.S.)
- United Therapeutics Corporation (U.S.)
- Actelion Pharmaceuticals Ltd. (Switzerland)
- F. Hoffmann-La Roche Ltd (Switzerland)
Intended Audience
- Medical Device Manufacturers
- Medical Device Suppliers
- Medical Research Laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Potential Investors
Report Attribute/Metric
|
Details
|
Market Size
|
USD 12.23 Billion by 2032
|
CAGR
|
7.14% (2024-2032)
|
Base Year
|
  2023
|
Forecast Period
|
  2024-2032
|
Historical Data
|
  2022
|
Forecast Units
|
 Value (USD Billion)
|
Report Coverage
|
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
|
Segments Covered
|
Types, end user, Region
|
Geographies Covered
|
America, Europe, Asia Pacific, Middle East and Africa
|
Key Vendors
|
Siemens (U.S.), Schiller AG, Midmark Corporation, Koninklijke Philips N.V. (Japan), Bionet (Korea), Welch Allyn (U.S.), Toshiba Medical Systems Corporation (Japan), AstraZeneca plc (U.K), Pfizer (U.S.), Sanofi (France), Merck & Co. (U.S.), Daiichi Sankyo Company Limited, Novartis AG (Germany), Bayer (Germany), Takeda Pharmaceutical Company Limited (Japan), Boehringer Ingelheim GmbH (Germany), Astellas Pharma Inc. (Japan), Johnson & Johnson (U.S.), United Therapeutics Corporation (U.S.), Actelion Pharmaceuticals Ltd. (Switzerland) and F. Hoffmann-La Roche Ltd (Switzerland)
|
Silent Heart Attack Market Highlights:
Frequently Asked Questions (FAQ) :
silent heart attack market is expected to register 7.14% CAGR from 2024 to 2032.
silent heart attack market is driven by high incidence of cardiovascular diseases.
High costs of diagnosis of heart conditions and lack of skilled professionals are factors which can hamper the global silent heart attack market.
The Americas can dominate the global silent heart attack market till 2032 due to rising cases of cardiovascular diseases.
Toshiba Medical Systems Corporation, Merck & Co., Takeda Pharmaceutical Company Limited, Bayer, Boehringer Ingelheim GmbH, Bionet, Midmark Corporation, Johnson & Johnson, United Therapeutics Corporation, Pfizer, Daiichi Sankyo Company Limited, Astellas Pharma Inc., F. Hoffmann-La Roche Ltd, Actelion Pharmaceuticals Ltd., Schiller AG, AstraZeneca plc, Sanofi, Welch Allyn, Koninklijke Philips N.V., Novartis AG, and Siemens are notable players of the global silent heart attack market.